[1]
M. Ferrario and G. Giuliani, “[In reference to "Clinical and economic evaluation of the introduction of the combinazion trametinib + dabrafenib in the management of advanced melanoma in the Italian market”]”, FE, vol. 18, no. 1, Sep. 2017.